Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides.

Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides. Abstract Text:

Putao Cen,Madeleine Duvic,Philip R Cohen,Razelle Kurzrock,

BACKGROUND: Mycosis fungoides, also called cutaneous T-cell lymphoma, comprise a group of extranodal, indolent non-Hodgkin's lymphomas of T-cell origin with primary involvement of the skin. There are few data available on tumor markers in these patients. Cancer antigen 27.29 (CA27.29), which is expressed on most carcinoma cells, is a soluble form of the glycoprotein MUC1. Measuring CA27.29 has been approved by the US Food and Drug Administration for monitoring disease activity in patients with breast cancer. OBJECTIVE: We sought to assess whether CA27.29 levels were increased in patients with cutaneous T-cell lymphoma and whether there was a correlation of this marker with tumor response. METHODS: We evaluated the CA27.29 blood levels from 6 patients with advanced mycosis fungoides (who had no evidence of breast cancer) and reviewed their charts for information about history and physical examinations, laboratory data, pathology findings, and radiologic examinations. RESULTS: We demonstrated that 3 of 6 patients with advanced mycosis fungoides had markedly elevated CA27.29 blood levels. In the two patients who had serial blood levels drawn, CA27.29 increased or decreased during treatment as the disease progressed or responded, respectively. LIMITATIONS: This study reflects pilot data on a limited number of patients. CONCLUSIONS: Our observations suggest that CA27.29 merits further investigation as a tumor marker in patients who have cutaneous T-cell lymphoma.

Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides. Publishing Authors By Initials

P Cen,M Duvic,PR Cohen,R Kurzrock,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of the American Academy of Dermatology

VOLUME: 58

Page Numbers: 382-6

Journal Abbreviation: J. Am. Acad. Dermatol.

ISSN: 1097-6787

DAY: 18

MONTH: Mar

YEAR: 2008

Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7907132

Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides.

AFFILIATION: Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Country: United States

AGENCY: United States NCRR

GRANT: RR024148

ACRONYM: RR

MEDLINETA: J Am Acad Dermatol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Increased cancer antigen 2729 CA2729 level in patients with mycosis fungoides Related Publications

• Beta1 integrin expression pattern in transitional urothelium does not allow for efficient stem cell enrichment as in other epithelia.
• Complete bladder duplication presenting as incontinence in an 11-year-old girl.
• Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.
• Cutaneous castleman's disease responds to anti interleukin-6 treatment.
• Development and validation of the fecal incontinence and constipation quality of life measure in children with spina bifida.
• Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials.
• How do we measure hypospadias outcomes?
• Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides.
• Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics.
• Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
• Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
• Non-surgical management of multicystic dysplastic kidney.
• Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies.
• Short stay pyeloplasty: variables affecting pain and length of stay.
• Studies in target-based treatment.
• The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.
• [Vinca rosea in the treatment of hemoblastoses and similar clinical pictures.]